Skip to Main Content

The Colombian government remains in the crosshairs of the pharmaceutical industry.

In comments filed with the US trade representative, the Pharmaceutical Research & Manufacturers of America argued that Colombia should be given added scrutiny for purportedly failing to sufficiently protect and enforce patent rights. The remarks from the trade group were submitted as the US Trade Rep prepares its priority watch list of countries that are singled out for practices deemed both favorable and unfavorable to American companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED